GutCore: An Endoscopy Foundation Model for Whole-Case Gastric Cancer Analysis
Kim, S.; Yoo, H.; Yoo, S.-K.; Lee, J.; Min, Y. W.; Lee, H.
Show abstract
Background and Aims: Endoscopic artificial intelligence is commonly validated on selected single images, whereas gastric cancer interpretation requires integrating whole examinations. We developed GutCore and evaluated whether whole-case endoscopic images could be used for patient-level assessment of gastric cancer depth, biomarkers, and prognosis. Methods: GutCore was pretrained on 5.6 million de-identified endoscopic images from more than ten hospitals. We compared it with five general, medical, and endoscopy-specific foundation models using open image-level datasets and an internal tertiary-center cohort of 11,035 de-identified endoscopic examinations (2019-2023): 8,049 with early or advanced gastric cancer and 2,986 with benign gastritis or intestinal metaplasia. All examination images were aggregated for patient-level assessment of cancer status, invasion depth, molecular biomarkers, and overall survival. Results: Aggregating all stored images from each examination enabled patient-level gastric cancer assessment without selecting representative frames. GutCore achieved AUCs of 0.995 for cancer detection, 0.960 for muscularis propria invasion, and 0.804 for SM2-or-deeper invasion. Prediction of tissue-defined biomarker status was strongest for Epstein-Barr virus status and MLH1 loss (AUC, 0.831 and 0.854), with lower HER2 performance (AUC, 0.673). In the held-out advanced gastric cancer test set, GutCore-derived risk groups showed marked survival separation (log-rank P < .0001; high-risk vs low-risk hazard ratio, 13.18; 95% CI, 6.06-28.66), with stratification persisting within pathological stage II and III disease. External frame-level benchmarks showed strong performance for anatomical landmark recognition, disease grading, and segmentation. Conclusions: GutCore supported whole-case patient-level gastric cancer assessment using routinely stored endoscopic images. Further validation in independent clinical cohorts is needed to establish generalizability and clinical utility.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.